Introduction
The Factor VIII molecular complex is comprised of two proteins-von Willebrand factor (vWf) (VIII C) (1, 2) . The vWf portion of the molecule is necessary for the adhesion of normal platelets to damaged endothelium, and it is defective or deficient in von Willebrand's disease (1) (2) (3) .
The vWf activity is most commonly measured in vitro by its ability to support ristocetin-induced agglutination of formalinfixed platelets; the in vivo stimulus for this reaction, however, is unknown (1) (2) (3) (4) (5) . Recent studies have demonstrated the binding of 1251-vWf to washed platelets by thrombin or ADP, thereby suggesting that these might be the physiologic stimuli for vWf binding in vivo (6) (7) (8) (9) . Although there was general agreement that ristocetin-induced vWf binding was to platelet membrane glycoprotein lb (GPIb) (10) (11) (12) , studies on the platelets from patients with Glanzmann's thrombasthenia and Bernard-Soulier syndrome suggested that thrombin-and ADP/epinephrine-induced vWf binding were mediated through GPIIb/IIIa (8, 9) . Furthermore, monoclonal antibodies (AP-1 and AP-2) to these GP (13) blocked the respective vWfbinding induced by ristocetin (GPIb) or thrombin and ADP/epinephrine (GPIIb/IIIa) (9, 13) . These studies (6-9) utilized purified, radiolabeled vWf with washed platelets and were not undertaken in the plasma milieu.
The preparations of vWf were shown to have all sizes of multimers (9) , but since they were obtained by column chromatography from the void volume fractions, the preparations might not have included all the normal plasma vWf multimers.
To study the binding of plasma vWf to platelets in the presence of normal plasma proteins, we developed a method that enabled us to label the vWfin normal plasma using a radiolabeled monoclonal antibody to the vWf protein. This monoclonal antibody did not inhibit the binding ofvWfto platelets by ristocetin, thrombin, or ADP/epinephrine, and identified all multimers of vWf. We were thereby able to measure the binding of vWf to platelets in the presence of normal plasma without the necessity of purifying the Factor VIII molecular complex. Since this monoclonal antibody was specific for vWf, trace labeling of fibrinogen or other plasma proteins that might contaminate purified vWf could be avoided.
mice by primary intraperitoneal immunization with 0.5 ml of Freund's complete adjuvant. Three subsequent intraperitoneal immunizations were given at 2-wk intervals followed by an intravenous immunization 4 d before hybridization. Fusion of the immune spleen cells with P3X63Ag8653 myeloma cells was carried out as previously described (13) . Positive hybrids were selected using a method of rocket inhibition of vWf antigen. This technique was modified from a method previously developed to detect the elution of polyspecific antibodies from a vWf immunoaffinity column (14) . Since monoclonal antibodies are usually nonprecipitating, the samples consisted of normal plasma and hybridoma spent media that were incubated for 30 min at room temperature and then incubated with 10 jg of rabbit anti-mouse IgG, which caused the precipitating reaction. Quantitative electrophoresis was carried out against '25W-labeled polyspecific antibody to vWf. Positive hybrids were demonstrated by inhibition of the vWf rockets (Fig. 1 ). This method was utilized because we were concerned about the potential alteration of antigenic specificity of purified vWf. Alternatively, an enzyme-linked immunosorbant assay was performed as previously described, except that vWfwas the immobilized antigen (13) . Positive hybrids were cloned and recloned by limiting cell dilution and ascites tumors established (13) . Two monoclonal antibodies were characterized and termed AVW-1 and AVW-2.
Purjfication and radiolabeling ofmonoclonal antibody. Monoclonal antibody was purified from ascites fluid by affinity chromatography with protein A-Sepharose 4B, as previously described (13) . These preparations were >95% homogeneous IgG by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Radiolabeling of the monoclonal antibody with 25I was done with the chloramine-T method (15) . The labeled IgG was separated from the unbound 1251 using a Sephadex G50 column. The purified, labeled IgG was then kept at 4°C in 10 mg/ml bovine serum albumin. The specific activity of this labeled IgG was 1-5 X 109 cpm/mg of IgG.
Preparation of albumin density gradient washed platelets. Plateletrich plasma was obtained from normal donors, a patient with severe von Willebrand's disease (<0.001IU/dl vWf antigen), and a patient with severe afibrinogenemia. Platelets were washed free of plasma constituents by sequential albumin density gradient centrifugations (16 and human a-thrombin, 0.5 U/ml. The platelet-bound vWfwas separated from the unbound supernatant vWf by centrifugation at 11,000 g for, 3 min in a fixed angle microcentrifuge (Eppendorf model 5412, Brinkmann Instruments, Inc., Westbury, NY). Since this was a fixed angle centrifuge, the small platelet pellet was on the side of the bottom of the microcentrifuge tube. This permitted complete aspiration of the fluid by placing the tip of the pipette down at the bottom of the tube. The supernate was carefully aspirated, and the remaining tip of the microcentrifuge tube containing the platelets was cut off. Both the supernate and the pellet were counted for 125I radioactivity in a gamma counter (Packard Instrument Co., Inc., Downers Grove, IL). All individual experiments were performed in duplicate and the results averaged. Controls included the same reactants, omitting the addition of the agonist. Typically the background '25I-vWf binding to platelets was 0.8-2.0% of the total radioactivity added.
In experiments where binding of vWfto thrombin-stimulated platelets was performed in the presence offibrinogen, hirudin (I U/ml) was added 5 min following the thrombin activation of platelets and before the addition of plasma or fibrinogen. This inactivated the residual thrombin and prevented clotting.
Inhibition ofvWfbinding by monoclonal antibodies to platelet membrane GPIb or GPIIb/IIIa. In some experiments, either AP-I or AP-AP-2 blocked the rebinding of the endogenous platelet vWf to these platelets, resulting in greater recovery of vWf in the supernate. Thus, they inhibited receptor interaction with vWf rather than inhibition of thrombin binding itself.
Effect ofA VW-I on the binding oflabeled purified vWfto platelets.
To substantiate the observation that excess AVW-1 did not inhibit thrombin-induced binding of vWf to platelets, vWf was purified from cryoprecipitate as previously described (17) and concentrated to 750 ,tg/ml in dialysis tubing using Sephadex G50. This vWfwas radiolabeled with 125I (sp act 25 X 103 cpm/,ug), as previously described (9) . Thrombininduced binding of this radiolabeled vWf (20 1ig/ml) was performed in the presence of 0-200 ug/ml of AVW-I and the percent inhibition of vWf binding was determined.
Quantitation of vWf The amount of vWf was measured by quantitative immunoelectrophoresis as previously described (14) . By staining, 3 U/dl of vWf could be detected, but by autoradiography as little as 0.001 U/dl could be measured.
Inhibition ofthrombin-induced vWfbinding to platelets byfibrinogen.
Purified human fibrinogen was the generous gift of Dr. M. W. Mosesson and Dr. D. L. Amrani, Mt. Sinai Medical Center, Milwaukee, WI. It was homogeneous by SDS-PAGE and contained <0.001 U/ml of vWf. Fibrinogen was added back to heat-defibrinated normal plasma or to afibrinogenemic plasma at various dilutions to determine the effect on thrombin-induced and ristocetin-induced vWfbinding. In the thrombin experiments, hirudin was added as described above.
Competition between vWfandfibrinogenfor thrombin-inducedplatelet binding. To determine whether there was competition between vWf and fibrinogen, purified vWf (750 g/ml) was labeled with radiolabeled AVW-1. Purified vWf had to be used so that high concentrations of vWf could be added. Since 800 gg/ml of fibrinogen was found to inhibit -50% of normal vWf binding, increasing concentrations of vWf (50-650 ,g/ ml) were added to determine whether this inhibition could be overcome.
Results
Monoclonal antibody to vWf Two monoclonal antibodies to vWf were developed. Positive hybrids were detected with the method of rocket inhibition, as demonstrated in Fig. 1 . With this method the screening antigen is normal plasma rather than a purified protein. This avoids possible antigenic restriction imposed by the purification by gel filtration of an antigen like vWf that has a marked variation in molecular size.
One of the monoclonal antibodies, termed AVW-1, recognized antigenic determinants on normal vWf, while the second monoclonal antibody, termed AVW-2, recognized antigenic determinants on both normal vWf and a fragment of vWf previously identified in commercial Factor VIII concentrate and in the plasma of patients with disseminated intravascular coagulation (14) . Although when normal plasma was utilized, both antibodies gave similar results, AVW-1 has been utilized in the subsequent studies.
Binding of vWf to platelets by ristocetin. Normal plasma vWf was labeled with radiolabeled AVW-1 and then added to formalin-fixed platelets or to albumin density gradient washed platelets. With formalin-fixed platelets, maximal binding was achieved with concentrations ofristocetin > 1.5 mg/ml at which 65-70% of the plasma vWf was bound to the platelets. When (Fig. 2) . However, if the same plasma was initially heat defibrinated, a dose-dependent vWf binding was found. Maximal vWf binding from heat-defibrinated normal plasma was obtained with thrombin doses > 0.1 U/ml. Although ristocetin induced >65% vWfbinding, only 25-35% of plasma vWf was bound to platelets by thrombin. The time course ofthrombin binding of vWf is shown in Fig. 3 . Maximal binding was reached at 30-40 min. This is similar to that reported for purified labeled vWf (6, 9 4 shows the specific binding of AVW-l labeled vWf to von Willebrand's disease platelets, when the platelet pellet was solubilized with Triton X-100 and analyzed by crossed immunoelectrophoresis against nonlabeled anti-vWf antisera. When heat-defibrinated von Willebrand's disease plasma was substituted for HDNP, no radioactive precipitin arc was seen.
Binding ofvWftoplatelets byADP/epinephrine. When ADP/ epinephrine-induced vWf binding was studied, no binding of vWf to platelets could be demonstrated when normal plasma was used. Following heat defibrination, however, 30-40% of plasma vWf was bound to the platelets-levels similar to those seen with thrombin (Fig. 5) . There was more variability in individual platelet responsiveness to ADP/epinephrine than with thrombin, although experiments performed on the same batch of platelets were highly reproducible (<10% variability).
Inhibition ofvWfbinding by monoclonal antibodies to GPIb and GPIIb/IIIa. Previous studies on purified vWf binding to platelets demonstrated inhibition of ristocetin-induced vWf binding by AP-1, a monoclonal antibody to GPIb, and inhibition of thrombin-induced vWf by AP-2, a monoclonal antibody to GPIIb/IIIa (9, 18). AP-2 blocks the monoclonal-labeled vWf binding to platelets induced by thrombin (>92%) and ADPepinephrine (>96%) but does not block the ristocetin-induced binding of vWf (Table I) Binding ofvWfto platelets in afibrinogenemic plasma. Since heating of plasma may alter proteins and/or proteases other than fibrinogen, the binding of vWf needed to be studied in hereditary afibrinogenemic plasma. The thrombin-induced vWf binding to afibrinogenemic platelets was similar for heat-defibrinated normal plasma or nonheated afibrinogenemic plasma (Fig. 6) . Likewise, ADP/epinephrine-induced vWf binding was similar in these two preparations (Fig. 5) . When monoclonallabeled platelet-rich afibrinogenemic plasma and washed afibrinogenemic platelets plus monoclonal-labeled afibrinogenemic plasma were compared, no differences could be demonstrated (data not shown).
Inhibition of thrombin-induced vWf binding by fibrinogen.
To study the direct inhibition ofthrombin-induced vWfbinding to platelets, purified fibrinogen was added back to the afibrinogenemic plasma or heat-defibrinated plasma. In these experiments hirudin was added after the thrombin activation of platelets to prevent clotting of the fibrinogen. At physiologic fibrinogen concentrations, >90% of the thrombin-induced binding of vWf is inhibited (Fig. 7) . This inhibition is dosedependent and is similar in heat-defibrinated normal plasma and afibrinogenemic plasma (data not shown). During intravascular consumption of fibrinogen, levels of fibrinogen commonly drop to <75 mg/dl. At these concentrations of fibrinogen, thrombin will induce significant vWf binding.
Competition between vWf and fibrinogen for thrombin-induced binding. At a concentration of fibrinogen (800 ug/ml) that inhibits 60% of the maximal vWf binding induced by thrombin at normal plasma concentrations of vWf, increased levels of vWf overcame this inhibition as shown in Table III.   Table II 
Discussion
The adhesion of platelets to damaged endothelium has been recognized as a function of plasma vWf for several years (1) (2) (3) (4) . This function has been studied in vitro with the induction of platelet agglutination by the antibiotic ristocetin (1, 2, 4) . Studies suggested that ristocetin mediated this response through the binding of vWf to platelet glycoprotein lb (10) (11) (12) . This was recently confirmed by the blocking of ristocetin-induced vWf binding with monoclonal antibodies to GPIb (9, 13, 18, 19) . The physiologic mechanism for this adhesion process in vivo has not been elucidated. When thrombin-induced and ADP/ epinephrine-induced vWf binding were demonstrated, a possible physiologic mechanism was suggested (5, 7). However, monoclonal antibody studies demonstrated that the binding site for vWf was different for these agonists and showed that thrombinand ADP/epinephrine-induced vWf binding was to GPIIb/IIIa and not to GPIb (9) . The recent reports demonstrating this thrombin-induced binding of vWf to platelets have used purified vWf and washed platelets (5, (7) (8) (9) . Although one report claimed a lack of inhibition of vWf binding by fibrinogen (5) Fibrinogen concentration (mg/ml) studied this binding in the presence of normal plasma proteins. Furthermore, the binding studies were performed with purified vWf. Since most methods for purifying vWf use molecular size as a major step in purification, this may result in the restriction of the size of the multimers separated because of the marked heterogeneity in molecular weight of the plasma vWf multimers. Therefore, a method was needed that would permit the labeling of all the plasma vWf multimers and would permit the binding to be performed in the presence of other plasma proteins. In the process of developing monoclonal antibodies to plasma vWf, A method for screening monoclonal antibody without purifying an antigen was also developed. This method permits the detection of hybridoma antibodies to vWf by "rocket inhibition" of normal plasma vWf when quantitative immunoelectrophoresis is carried out against polyspecific rabbit anti-vWf. This method has been applied to the detection of monoclonal antibodies to platelet membrane GP (Kunicki, T. J., and R. R. Montgomery, unpublished observations). This method is particularly helpful when a complex polyspecific antibody is available (i.e., anti-whole platelet antisera) and a crude immunogen is used. Multiple monoclonal antibodies may be detected without purifying each individual protein for individual monoclonal screening. If a precipitating polyspecific antibody is available for a given antigen, even normal plasma may be used as the source for screening antigen.
